First Patient Treated in Ph 1 Trial of PHST001 for Patients with Advanced Solid Tumors April 22, 2025
US FDA Grants Full Approval of VITRAKVI (larotrectinib) for Adult and Pediatric Patients with NTRK Gene Fusion-Positive Solid Tumors April 16, 2025
Edity Therapeutics and Aurigene Oncology to Advance a Novel Cell Therapy Program for Solid Tumors April 8, 2025
FDA Clears IND Application for Ph 1 Trial of RB-164 for Hematologic and Solid Malignancies April 8, 2025
Boehringer Ingelheim strengthens ADC portfolio with new NBE Therapeutics R&D center in Basel April 8, 2025
FDA clears IND application for ALX2004 for the treatment of EGFR-expressing solid tumors April 8, 2025
SC Pembrolizumab With Berahyaluronidase Alfa Demonstrates Noninferior PK Compared to IV KEYTRUDA in Pivotal 3475A-D77 Trial April 2, 2025
Positive CHMP Opinion for the SC Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications April 2, 2025
FDA Clears IND Application for Ph 1 Trial of RB-164 for Hematologic and Solid Malignancies April 2, 2025
iOncologi, Inc. Acquires TargImmune Therapeutics to Expand and Strengthen Immunotherapy Pipeline Against Solid Tumors March 18, 2025
BioCity Biopharmaceutics Announces Clinical Collaboration to Evaluate BC3195 + KEYTRUDA combination in Patients with Locally Advanced or Metastatic Solid Tumors March 18, 2025
Pierre Fabre Laboratories and RedRidge Bio Announce Drug Discovery and Co-development Partnership March 12, 2025
